Is a 503B compounding pharmacy FDA-approved?

A 503B outsourcing facility is FDA-registered and subject to ongoing FDA inspection under current Good Manufacturing Practice (cGMP) regulations, but its compounded products are not individually FDA-approved the way a manufactured drug under a New Drug Application (NDA) is. The distinction matters for sponsor MSAs, hospital purchase contracts, and insurance program structure.

503B facilities operate under Section 503B of the Federal Food, Drug, and Cosmetic Act, added by the Drug Quality and Security Act of 2013. They register with FDA, are inspected on a risk-based schedule, and must comply with cGMP regulations. They may compound from bulk drug substances on FDA's positive list and sell to hospitals and clinics without patient-specific prescriptions.

The compounded products themselves are not subject to the NDA approval process. This is a substantive regulatory distinction: an NDA-approved drug carries an FDA finding of safety and efficacy for the labeled indication; a 503B compounded preparation carries no such finding, only cGMP compliance for its production.

Hospital purchase contracts that reference "FDA-approved" products need to be reviewed carefully when sourcing from 503Bs. Insurance schedules need to address the 503B regulatory category specifically.